Effects of a nutraceutical combination (berberine, red yeast rice and policosanols) on lipid levels and endothelial function randomized, double-blind, placebo-controlled study

Nutrition, Metabolism and Cardiovascular Diseases

Volumn 20, Issue 9, 2010, Pages 656-661

  Affuso, F ^a   Ruvolo, A ^a   Micillo, F ^a   Sacca L ^a   Fazio, S ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Endothelial function; Hyperlipidemia; Insulin resistance; Nutraceutical

Indexed keywords

BERBERINE; BIOLOGICAL PRODUCT; CHOLESTEROL; CHOLESTIN; FATTY ALCOHOL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; POLICOSANOL; TRIACYLGLYCEROL;

ARTICLE; BLOOD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET SUPPLEMENTATION; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; INSULIN RESISTANCE; MALE; MIDDLE AGED; PATHOPHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; VASCULAR ENDOTHELIUM;

ANTICHOLESTEREMIC AGENTS; BERBERINE; BIOLOGICAL PRODUCTS; CHOLESTEROL; CHOLESTEROL, LDL; DIETARY SUPPLEMENTS; DOUBLE-BLIND METHOD; ENDOTHELIUM, VASCULAR; FATTY ALCOHOLS; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; INSULIN RESISTANCE; MALE; MIDDLE AGED; PLACEBOS; TRIGLYCERIDES;

EID: 78049406766     PISSN: 09394753     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.numecd.2009.05.017     Document Type: Article

References (28)

1. Rosamond W., Flegal K., Furie K., Go A., Greenlund K., Haase N., et al. American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics 2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2008, 117:e25-e146.
2. Endemann D.H., Schiffrin E.L. Endothelial dysfunction. J Am Soc Nephrol 2004, 15:1983-1992.
3. Henry P.D., Cabello O.A., Chen C.H. Hypercholesterolemia and endothelial dysfunction. Curr Opin Lipidol 1995, 6:190-195.
4. Martinez-Gonzalez J., Raposo B., Rodriguez C., Badimon L. 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibition prevents endothelial NO synthase downregulation by atherogenic levels of native LDLs: balance between transcriptional and posttranscriptional regulation. Arterioscler Thromb Vasc Biol 2001, 21:804-809.
5. Montagnani M., Ravichandran L.V., Chen H., Esposito D.L., Quon M.J. Insulin receptor substrate-1 and phosphoinositide-dependent kinase-1 are required for insulin-stimulated production of nitric oxide in endothelial cells. Mol Endocrinol 2002, 16:1931-1942.
6. Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002, 106:3143-3421.
7. Nissen S.E., Tuzcu E.M., Schoenhagen P., Crowe T., Sasiela J.W., Tsai J., et al. Reversal of atherosclerosis with aggressive lipid lowering (REVERSAL) investigators. Statin therapy, LDL cholesterol, C-ractive protein, and coronary artery disease. N Engl J Med 2005, 352:29-38.
8. Kamal-Bahl S.J., Burke T., Watson D., Wentworth C. Discontinuation of lipid modifying drugs among commercially insured United States patients in recent clinical practice. Am J Cardiol 2007, 99:530-534.
9. Schultz J.S., O'Donnell J.C., McDonough K.L., Sasane R., Meyer J. Determinants of compliance with statin therapy and low-density lipoprotein cholesterol goal attainment in a managed care population. Am J Manag Care 2005, 11:306-312.
10. Caspard H., Chan A.K., Walker A.M. Compliance with a statin treatment in a usual-care setting: retrospective database analysis over 3 years after treatment initiation in health maintenance organization enrollees with dyslipidemia. Clin Ther 2005, 27:1639-1646.
11. Chen J.T., Wesley R., Shamburek R.D., Pucino F., Csako G. Meta-analysis of natural therapies for hyperlipidemia: plant sterols and stanols versus policosanol. Pharmacotherapy 2005, 25:171-183.
12. Heber D., Yip I., Ashley J.M., Elashoff D.A., Elashoff R.M., Go V.L. Cholesterol-lowering effects of a proprietary Chinese red-yeast-rice dietary supplement. Am J Clin Nutr 1999, 69:231-236.
13. Zhang Y., Li X., Zou D., Liu W., Yang J., Zhu N., et al. Treatment of type 2 diabetes and dyslipidemia with the natural plant alkaloid berberine. J Clin Endocrinol Metab 2008, 93(7):2559-2565.
14. Xu M.G., Wang J.M., Chen L., Wang Y., Yang Z., Tao J. Berberine-induced upregulation of circulating endothelial progenitor cells is related to nitric oxide production in healthy subjects. Cardiology 2008, 112:279-286.
15. Lee Y.S., Kim W.S., Kim K.H., Yoon M.J., Cho H.J., Shen Y., et al. Berberine, a natural plant product, activates AMP-activated protein kinase with beneficial metabolic effects in diabetic and insulin-resistant states. Diabetes 2006, 55:2256-2264.
16. Corretti M.C., Anderson T.J., Benjamin E.J., Celermajer D., Charbonneau F., Creager M.A., et al. International brachial artery reactivity task force. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol 2002, 39:257-265.
17. McAuley K.A., Williams S.M., Mann J.I., Walker R.J., Lewis-Barned N.J., Temple L.A., et al. Diagnosing insulin resistance in the general population. Diabetes Care 2001, 24(3):460-464.
18. Matsuda M., DeFronzo M.R.A. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglicemic clamp. Diabetes Care 1999, 22:1462-1470.
19. Cicero A.F., Rovati L.C., Setnikar I. Eulipidemic effects of berberine administered alone or in combination with other natural cholesterol-lowering agent. A single blind clinical investigation. Arzneimittel-forshung 2007, 57:26-30.
20. Kong W., Wei J., Abidi P., Lin M., Inaba S., Li C., et al. Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins. Nat Med 2004, 10:1344-1351.
21. Brusq J.M., Ancellin N., Grondin P., Guillard P., Martin S., Saintillan Y., et al. Inhibition of lipid synthesis through activation of AMP-Kinase: an additional mechanism for the hypolipidemic effects of berberine. J Lipid Res 2006, 47:1281-1288.
22. Singh D.K., Li L., Porter T.D. Policosanol inhibits cholesterol synthesis in hepatoma cells by activation of AMP-kinase. J Pharmacol Exp Ther 2006, 318:1020-1026.
23. Journoud M., Jones P.J. Red yeast rice: a new hypolipidemic drug. Life Sci 2004, 74:2675-2683.
24. Kong W.J., Zhang H., Song D.Q., Xue R., Zhao W., Wei J., et al. Berberine reduces insulin resistance through protein kinase C-dependent up-regulation of insulin receptor expression. Metabolism 2009, 58:109-119.
25. Liu J., Zhang J., Shi Y., Grimsgaard S., Alraek T., Fønnebø V. Chinese red yeast rice (Monascus purpureus) for primary hyperlipidemia: a meta-analysis of randomized controlled trials. Chinas Med 2006, 1:4.
26. Gouni-Berthold I., Berthold H.K. Policosanol: clinical pharmacology and therapeutic significance of a new lipid-lowering agent. Am Heart J 2002, 143:356-365.
27. Berthold H.K., Unverdorben S., Degenhardt R., Bulitta M., Gouni-Berthold I. Effect of policosanol on lipid levels among patients with hypercholesterolemia or combined hyperlipidemia: a randomized controlled trial. J Am Med Assoc 2006, 295:2262-2269.
28. Kassis A.N., Jones P.J. Changes in cholesterol kinetics following sugar cane policosanol supplementation: a randomized control trial. Lipids Health Dis 2008, 30:7-17.